Biosynthesis of prostaglandin D2 1. Formation of prostaglandin D2 by human platelets
References (22)
- et al.
Isolation and properties of intermediates in prostaglandin biosynthesis
Biochim. Biophys. Acta
(1973) - et al.
Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle
Prostaglandins
(1973) - et al.
Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes
Biochim. Biophys. Acta
(1975) - et al.
Metabolism and effects of prostaglandin H2 in adipose tissue
Prostaglandins
(1976) - et al.
Factors affecting prostaglandin synthesis by rat skin microsomes
Prostaglandins
(1976) - et al.
Isomerization of prostaglandin H2 into prostaglandin D2 in the presence of serum albumin
Biochim. Biophys. Acta
(1976) - et al.
Prostaglandin D2 as a potential antithrombotic agent
Prostaglandins
(1975) - et al.
Effects of feeding ethyl-dihomo-γ-linolenate on prostaglandin biosynthesis and platelet aggregation in the rabbit
Biochim. Biophys. Acta
(1976) - et al.
High performance liquid chromatography of prostaglandins: Biological applications
Prostaglandins
(1976) - et al.
Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis
Proc. Nat. Acad. Sci. USA
(1973)
Biosynthesis of prostaglandins in rabbit kidney medulla
Properties of prostaglandin synthase
Biochem. J.
Cited by (101)
Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D<inf>2</inf> in mice and humans
2008, Journal of Biological ChemistryCitation Excerpt :Furthermore, tetranor PGDM is thus far uniquely detectable in mouse urine, affording the possibility of integrating estimates of biosynthesis with experimental manipulations in mice in which elements of the PGD2 synthesis/response system have been genetically manipulated. Future studies may reveal biological activity for this metabolite, but unlike PGD2 itself, it failed to inhibit platelet aggregation, an effect transduced via DP1 (12, 13). Formation of urinary tetranor PGDM is altered by modulation of PGD2 biosynthesis in both mice and humans.
The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARγ ligands
2007, Prostaglandins and Other Lipid MediatorsProstaglandin D<inf>2</inf> receptor-mediated desensitization of the α isoform of the human thromboxane A<inf>2</inf> receptor
2001, Biochemical PharmacologyCitation Excerpt :Whereas recent evidence indicates that both TP isoforms may couple to members of the G12 family [20–22], they may oppositely regulate adenylyl cyclase activity [23], and TPα, but not TPβ, has been proposed to couple to Gh [24]. Prostaglandin (PG) D2, like prostacyclin, is a potent inhibitor of platelet aggregation [25,26]. Two distinct PGD synthases catalyse the isomerisation of PGH2 to PGD2: one is the lipocalin type that was previously known as the brain-type enzyme or gluthathione-independent type, and the other is the hematopoietic type or gluthathione-dependent type [27].
Analyses of prostaglandin D<inf>2</inf> metabolites in urine: Comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography- mass spectrometry
1999, Prostaglandins and Other Lipid MediatorsMarkers of mast cell degranulation
1997, Methods: A Companion to Methods in EnzymologyPlatelet prostanoid receptors
1996, Pharmacology and Therapeutics